Key result
Biomarkers offer various clinical applications in the evaluation and management of CHD.
Why the study?
Developments in genomic discovery have yielded new candidates for cardiovascular disease biomarkers and therapeutic targets, but their clinical application and challenges require review.
Key points are not available for this paper at this time.
Design
Brief review of recent trends in cardiovascular disease biomarkers
May support cautious biomarker integration in CHD care; leaves open prospective validation before practice change.
Cardiovascular disease is a major health concern globally. Genetic testing is an attractive tool for cardiovascular disease prediction because it is a low-cost, high-fidelity technology with multiplex capability. Developments in genomic discovery have yielded valuable new candidates in the quest for better biomarkers and novel therapeutic targets. This brief review focuses on recent trends in biomarkers of cardiovascular disease. DNA microarrays, single nucleotide polymorphism chips, linkage analysis, genome-wide association studies, and other strategies have increased our knowledge of metabolic diseases of the heart. This review also examines the potential applications and challenges of using genetic information for predicting cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2015) studied this question. Biomarkers have various clinical applications in the evaluation and management of coronary heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: